Woodline Partners LP Decreases Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE)

Woodline Partners LP decreased its stake in Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 53.6% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,422,785 shares of the biopharmaceutical company's stock after selling 1,642,962 shares during the quarter. Woodline Partners LP owned about 1.25% of Fate Therapeutics worth $2,348,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Intech Investment Management LLC boosted its holdings in shares of Fate Therapeutics by 27.5% in the 4th quarter. Intech Investment Management LLC now owns 39,443 shares of the biopharmaceutical company's stock worth $65,000 after purchasing an additional 8,497 shares during the period. SG Americas Securities LLC boosted its holdings in shares of Fate Therapeutics by 30.6% in the 4th quarter. SG Americas Securities LLC now owns 44,874 shares of the biopharmaceutical company's stock worth $74,000 after purchasing an additional 10,511 shares during the period. American Century Companies Inc. boosted its holdings in shares of Fate Therapeutics by 6.6% in the 4th quarter. American Century Companies Inc. now owns 197,704 shares of the biopharmaceutical company's stock worth $326,000 after purchasing an additional 12,295 shares during the period. Franklin Resources Inc. boosted its holdings in shares of Fate Therapeutics by 9.6% in the 4th quarter. Franklin Resources Inc. now owns 165,353 shares of the biopharmaceutical company's stock worth $273,000 after purchasing an additional 14,532 shares during the period. Finally, ProShare Advisors LLC boosted its holdings in shares of Fate Therapeutics by 77.9% in the 4th quarter. ProShare Advisors LLC now owns 33,645 shares of the biopharmaceutical company's stock worth $56,000 after purchasing an additional 14,728 shares during the period. Hedge funds and other institutional investors own 97.54% of the company's stock.

Fate Therapeutics Trading Down 3.4%

Shares of FATE traded down $0.05 during midday trading on Friday, reaching $1.28. 420,558 shares of the stock were exchanged, compared to its average volume of 2,221,548. Fate Therapeutics, Inc. has a 52 week low of $0.66 and a 52 week high of $5.92. The company's 50 day moving average is $1.06 and its two-hundred day moving average is $1.43. The company has a market capitalization of $146.12 million, a P/E ratio of -0.77 and a beta of 2.32.

Fate Therapeutics (NASDAQ:FATE - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.39) by $0.07. Fate Therapeutics had a negative return on equity of 45.88% and a negative net margin of 1,325.43%. The business had revenue of $1.63 million for the quarter, compared to the consensus estimate of $1.18 million. On average, sell-side analysts expect that Fate Therapeutics, Inc. will post -1.63 EPS for the current year.

Wall Street Analysts Forecast Growth

FATE has been the subject of a number of recent research reports. Barclays dropped their target price on Fate Therapeutics from $10.00 to $2.00 and set an "overweight" rating for the company in a report on Wednesday, May 14th. Wall Street Zen raised Fate Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, May 15th. Wells Fargo & Company cut their price objective on Fate Therapeutics from $5.00 to $4.00 and set an "equal weight" rating on the stock in a research report on Thursday, March 6th. Robert W. Baird cut their price objective on Fate Therapeutics from $5.00 to $4.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 14th. Finally, Stifel Nicolaus cut their price objective on Fate Therapeutics from $5.00 to $3.00 and set a "hold" rating on the stock in a research report on Thursday, March 6th. Eight research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $4.14.

About Fate Therapeutics

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.